IFNA1 and COVID-19: Recently, Hadadji et al. reported that impaired type I IFN activity (characterized by no IFN-β and low IFN-α production) and exacerbated inflammatory responses in severe COVID-19 patients [100] provide insights into the treatment of severe COVID-19 through induction/adjusting host type I IFN response.